Is Bio­gen the most des­per­ate buy­er scout­ing the biotech mar­ket?

There are sev­er­al big play­ers in biotech who would clear­ly love to make a splashy ac­qui­si­tion. A rich Gilead ($GILD), now that the bloom is com­ing off its hep C rose, is one. Ab­b­Vie ($AB­BV), be­cause its last big ex­cit­ing ac­qui­si­tion – Stem­cen­trx – im­me­di­ate­ly lost lus­ter at AS­CO. Al­ler­gan ($AGN) has the mon­ey and a deal­mak­ing CEO who likes to think big.

And Pfiz­er ($PFE) makes the list, be­cause, well, you name it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Recon Strategy

Boston, MA, USA